Non-small cell lung cancer · 11 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin, Pemetrexed, RT Variant #01 | — | R 40 999 | 63d | — | — | ~1 | ~R 40 999 indirect | — |
Cisplatin, Vinblastine, RT Variant #01 | — | R 8 397 | 35d | — | — | ~1 | ~R 8 397 indirect | — |
Cisplatin and Docetaxel (DC) and RT Variant #01 | — | R 4 778 | 35d | — | — | ~1 | ~R 4 778 indirect | — |
Carboplatin and Paclitaxel (CP) and RT Variant #01 | — | R 3 809 | 35d | — | ~18.2 mo | ~1 | ~R 3 809 PFS proxy · indirect | 1 |
Carboplatin and RT Variant #01 | — | R 3 746 | 42d | — | ~22.4 mo | ~1 | ~R 3 746 PFS proxy · indirect | 1 |
Carboplatin, Vinorelbine, RT Variant #01 | — | R 3 168 | 21d | — | ~12.6 mo | ~4 | ~R 12 671 PFS proxy · indirect | — |
Cisplatin and Vinorelbine (CVb) and RT Variant #01 | — | R 3 154 | 42d | — | — | ~1 | ~R 3 154 PFS proxy · indirect | 1 |
MVP and RT Variant #01 Partial | — | R 2 257 | 46d | — | ~20.5 mo | ~4 | ~R 9 027 PFS proxy · indirect | — |
Cisplatin and RT Variant #01 | — | R 588 | 49d | ~5.3 mo | — | ~1 | ~R 588 PFS proxy · indirect | — |
Radiation therapy N/A - radiation | — | — | 49d | ~5.1 mo | ~12.0 mo | — | — | 1 |
Cisplatin, Etoposide, RT Partial | — | — | — | — | — | — | — | — |
11 of 11 regimens shown